ClinicalTrials.gg
CompletedNCT03474679Updated Feb 4, 2025Results posted

A Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)

A Phase 3 interventional study of Ibrutinib in Graft vs Host Disease, sponsored by Janssen Pharmaceutical K.K.. Completed at 15 sites in Japan. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-02-04.

Sponsored by Janssen Pharmaceutical K.K. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
19
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies in Graft vs Host Disease with a site in Japan — 1 open to participants now, 2 under way, none of them phase 3. Graft vs Host Disease · Japan.

Started
2018
with 1 other
Phase 3
4 of 13
none open now
Registered
8th of 13
by date
Lead sponsor
1 of 13
Janssen Pharmaceutical K.K.

Among the 13 studies in Graft vs Host Disease with a site in Japan, this one is one of 2 that started in 2018, is one of 4 in phase 3, and was the 8th registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 149 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

1 of the 13 studies in Graft vs Host Disease with a site in Japan is open now. Recruiting first, the newest first:

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 103 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 42 (41%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Graft vs Host Disease with a site in Japan, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate efficacy of ibrutinib in Japanese participants with steroid dependent/refractory chronic graft versus host disease (cGVHD) by measuring overall cGVHD response (complete response [CR] and partial response [PR] defined by National Institutes of Health [NIH] consensus development project criteria [2014]).

03

Conditions studied

  • Graft vs Host Disease

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • dependent/ chronic (cGVHD) defined as modified National Institutes of Health (NIH) criteria (2014) below at any time post-hematopoietic cell transplant (post-HCT): a) Dependent disease, defined as, when glucocorticoid (prednisolone doses greater than or equal to [>=] 0.25 milligram per kilogram per day (mg/kg/day)or >=0.5 milligram per kilogram (mg/kg) every other day) are needed to prevent recurrence or progression of manifestations as demonstrated by unsuccessful attempts to taper the dose to lower levels on at least 2 occasions, separated by at least 8 weeks. In case of inability to taper the dose to less than or equal to (\<=)0.25 mg/kg/day or \<=0.5 mg/kg every other day (prednisolone doses) due to recurrence or progression of cGVHD manifestations, it is considered as steroid-dependent disease if the lowest tapering dose of the second occasion is equal or higher than the lowest tapering dose of the first occasion; b) Refractory disease, defined as, when cGVHD manifestations progress despite the use of a regimen containing glucocorticoid (prednisolone at >=1 mg/kg/day for at least 1 week) or persist without improvement despite continued treatment with glucocorticoid (prednisolone at >=0.5 mg/kg/day or 1 mg/kg every other day) for at least 4 weeks
  • Participants must be receiving baseline systemic glucocorticoid therapy for cGVHD at study entry. The dose of steroids must be stable for 14 days prior to starting ibrutinib
  • At the time of trial enrollment, participants may be receiving other therapies in addition to glucocorticoids. Immunosuppressant doses must be stable for 14 days prior to starting ibrutinib
  • Clinically stable or worsening cGVHD for a minimum of 14 days between screening and Day 1 cGVHD response assessment
  • or Lansky (participants less than [\<]16 years) performance status >=60

Exclusion criteria

Exclusion Criteria:

  • Active acute (GVHD)
  • More than 3 previous systemic treatments for cGVHD. Treatment with is considered a treatment for cGVHD and should be included in determining the number of previous treatments
  • History of treatment with a tyrosine kinase inhibitor (example [e.g.] imatinib), purine analogs, or other cancer chemotherapy in the 4 weeks prior to starting ibrutinib. Participants may have received ibrutinib pre-transplant for other reasons besides cGVHD such as for the treatment of leukemia or lymphoma
  • History of treatment with monoclonal T and B cell antibodies in the 8 weeks prior to starting ibrutinib
  • Vaccinated with live, attenuated vaccines within 4 weeks of first dose of ibrutinib
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Ibrutinib

    Participants will receive 420 milligram (mg) oral ibrutinib once daily starting on Week 1 Day 1, unless they have intervening unacceptable toxicity or meet other criteria for participants discontinuation.

    Drug: Ibrutinib

Interventions

  • Participants will receive 420 mg (3 \* 140 mg capsules) oral ibrutinib once daily starting on Week 1 Day 1, unless they have intervening unacceptable toxicity or meet other criteria for participants discontinuation.

    Also known as: PCI-32765, JNJ-54179060

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    ORR is defined as the percentage of participants who achieve complete response (CR) or partial response (PR) in the absence of new therapy for chronic graft versus host disease (cGVHD) and absence of progression of underlying disease or death based on the National Institutes of Health (NIH) Consensus Development Project Criteria (2014). CR is defined as resolution of all manifestations in each organ or site; PR is defined as improvement in at least 1 organ or site without progression in any other organ or site; and chronic graft versus host disease (cGVHD) progression is defined as clinically meaningful worsening in 1 or more organs regardless of improvement in other organs.

    Time frame: Up to 3 year 6 months

Secondary outcomes

  1. Sustained Response Rate

    Sustained response rate was defined as percentage of participants with NIH defined CR or PR that was sustained for at least 20 weeks. CR is defined as resolution of all manifestations in each organ or site; PR is defined as improvement in at least 1 organ or site without progression in any other organ or site.

    Time frame: Up to 3 year 6 months

  2. Duration of Response (DOR)

    DOR is defined as the duration from the date of initial response (CR or PR) to the date of progressive cGVHD or death, whichever occurred first. CR is defined as resolution of all manifestations in each organ or site; PR is defined as improvement in at least 1 organ or site without progression in any other organ or site; and cGVHD progression is defined as clinically meaningful worsening in 1 or more organs regardless of improvement in other organs.

    Time frame: Up to 3 year 6 months

  3. cGVHD Response Rate at Each Timepoints

    cGVHD response rate was defined as percentage of participants with NIH defined CR or PR at each timepoint. CR is defined as resolution of all manifestations in each organ or site; PR is defined as improvement in at least 1 organ or site without progression in any other organ or site.

    Time frame: Weeks 5, 13, 25, 37, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157

  4. Change in the Amount of Corticosteroid Required Over Time

    Change in the amount of corticosteroid required over time was reported.

    Time frame: Baseline, Weeks 24, 48, 96, and 144

  5. Percentage of Participants With Overall Improvement in Lee cGVHD Symptom Scale Score

    Percentage of participants with overall improvement in Lee cGVHD symptom scale score was reported. Lee cGVHD symptom scale is a patient-reported symptom scale used to measure symptom burden and has 7 subscales (Skin, Eyes and Mouth, Breathing, Eating and Digestion, Muscles and Joints, Energy, and Mental and Emotional) with ratings as follows: 0-Not at all, 1-Slightly, 2-Moderately, 3-Quite a bit, 4-Extremely, with lower values representing a better outcome. A score was calculated for each subscale by taking the mean of all items completed if more than 50% were answered and normalizing to a 0 to 100 with a higher score indicating worse symptoms. An overall score was calculated as the average of these 7 subscales if at least 4 subscales had valid scores. A change of greater than or equal to (\>=) 7 points on the Lee cGVHD symptom scale overall score was considered significant and relates to improvement in quality of life (QoL).

    Time frame: Up to 3 year 6 months

  6. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs are adverse events with onset during the treatment phase or that were a consequence of a preexisting condition that has worsened since baseline, and occurred during treatment or within 30 days following the last dose of study treatment, or any adverse event that was considered study treatment-related regardless of the start date of the event.

    Time frame: Up to 3 year 6 months

  7. Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Measurable Concentration (AUC [0-last]) of Ibrutinib

    AUC(0-last) is defined as area under the plasma concentration-time curve from time zero to time of last measurable concentration of ibrutinib.

    Time frame: Day 1 of Weeks 1 and 2

  8. Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours (AUC [0-24]) of Ibrutinib

    AUC(0-24) is defined as area under the plasma concentration-time curve from time zero to 24 hours of ibrutinib.

    Time frame: 0 to 24 hours (Day 1 of Weeks 1 and 2)

  9. Maximum Observed Plasma Concentration (Cmax) of Ibrutinib

    Cmax is defined as maximum observed plasma concentration of ibrutinib.

    Time frame: Day 1 of Weeks 1 and 2

  10. Time to Reach Maximum Observed Plasma Concentration (Tmax) of Ibrutinib

    Tmax is defined as time to reach the maximum observed plasma concentration of ibrutinib.

    Time frame: Day 1 of Weeks 1 and 2

  11. Elimination Half-Life (t1/2) of Ibrutinib

    T1/2 is defined as elimination half-life of ibrutinib.

    Time frame: Day 1 of Weeks 1 and 2

  12. Apparent Clearance (CL/F) of Ibrutinib

    CL/F is defined as apparent clearance of ibrutinib.

    Time frame: Day 1 of Weeks 1 and 2

  13. Apparent Volume of Distribution (Vd/F) of Ibrutinib

    Vd/F is defined as apparent volume of distribution of ibrutinib.

    Time frame: Day 1 of Weeks 1 and 2

  14. Area Under the Plasma Concentration-time Curve From Time Zero to Infinite Time (AUC[0-infinity]) of Ibrutinib

    AUC(0-infinity) is defined as area under the plasma concentration-time curve from time zero to infinite time of ibrutinib.

    Time frame: Day 1 of Weeks 1 and 2

  15. Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Measurable Concentration (AUC [0-last]) of PCI-45227

    AUC(0-last) is defined as area under the plasma concentration-time curve from time zero to time of last measurable concentration of PCI-45227.

    Time frame: Day 1 of Weeks 1 and 2

  16. Area Under the Plasma Concentration-Time Curve From Time Zero to 24 Hours (AUC [0-24]) of PCI-45227

    AUC(0-24) is defined as area under the plasma concentration-time curve from time zero to 24 hours of PCI-45227.

    Time frame: 0 to 24 hours (Day 1 of Weeks 1 and 2)

  17. Maximum Observed Plasma Concentration (Cmax) of PCI-45227

    Cmax is defined as maximum observed plasma concentration of PCI-45227.

    Time frame: Day 1 of Weeks 1 and 2

  18. Time to Reach Maximum Observed Plasma Concentration (Tmax) of PCI-45227

    Tmax is defined as time to reach the maximum observed plasma concentration of PCI-45227.

    Time frame: Day 1 of Weeks 1 and 2

  19. Elimination Half-Life (t1/2) of PCI-45227

    T1/2 is defined as elimination half-life of PCI-45227.

    Time frame: Day 1 of Weeks 1 and 2

  20. Apparent Clearance (CL/F) of PCI-45227

    CL/F is defined as apparent clearance of PCI-45227.

    Time frame: Day 1 of Weeks 1 and 2

  21. Apparent Volume of Distribution (Vd/F) of PCI-45227

    Vd/F is defined as apparent volume of distribution of PCI-45227.

    Time frame: Day 1 of Weeks 1 and 2

  22. Area Under the Plasma Concentration-time Curve From Time Zero to Infinite Time (AUC[0-infinity]) of PCI-45227

    AUC(0-infinity) is defined as area under the plasma concentration-time curve from time zero to infinite time of PCI-45227.

    Time frame: Day 1 of Weeks 1 and 2

07

Results

Posted Feb 3, 2023

Participant flow

Participant flow — Overall Study
MilestoneIbrutinib 420 mg
Started19
Completed11
Not completed8
Withdrew: Death7
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryOverall Response Rate (ORR)

ORR is defined as the percentage of participants who achieve complete response (CR) or partial response (PR) in the absence of new therapy for chronic graft versus host disease (cGVHD) and absence of progression of underlying disease or death based on the National Institutes of Health (NIH) Consensus Development Project Criteria (2014). CR is defined as resolution of all manifestations in each organ or site; PR is defined as improvement in at least 1 organ or site without progression in any other organ or site; and chronic graft versus host disease (cGVHD) progression is defined as clinically meaningful worsening in 1 or more organs regardless of improvement in other organs.

Time frame:
Up to 3 year 6 months
Reported as:
Number · Percentage of participants
Overall Response Rate (ORR)
Percentage of participantsIbrutinib 420 mg
Overall Response Rate (ORR)84.2
SecondarySustained Response Rate

Sustained response rate was defined as percentage of participants with NIH defined CR or PR that was sustained for at least 20 weeks. CR is defined as resolution of all manifestations in each organ or site; PR is defined as improvement in at least 1 organ or site without progression in any other organ or site.

Time frame:
Up to 3 year 6 months
Reported as:
Number · Percentage of participants
Sustained Response Rate
Percentage of participantsIbrutinib 420 mg
Sustained Response Rate68.8
SecondaryDuration of Response (DOR)

DOR is defined as the duration from the date of initial response (CR or PR) to the date of progressive cGVHD or death, whichever occurred first. CR is defined as resolution of all manifestations in each organ or site; PR is defined as improvement in at least 1 organ or site without progression in any other organ or site; and cGVHD progression is defined as clinically meaningful worsening in 1 or more organs regardless of improvement in other organs.

Time frame:
Up to 3 year 6 months
Reported as:
Median · Months
Duration of Response (DOR)
MonthsIbrutinib 420 mg
Duration of Response (DOR)NA (5.30 to NA)
SecondarycGVHD Response Rate at Each Timepoints

cGVHD response rate was defined as percentage of participants with NIH defined CR or PR at each timepoint. CR is defined as resolution of all manifestations in each organ or site; PR is defined as improvement in at least 1 organ or site without progression in any other organ or site.

Time frame:
Weeks 5, 13, 25, 37, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157
Reported as:
Number · Percentage of participants
cGVHD Response Rate at Each Timepoints
Percentage of participantsIbrutinib 420 mg
Week 526.3 (9.1 to 51.2)
Week 1342.1 (20.3 to 66.5)
Week 2552.6 (28.9 to 75.6)
Week 3747.4 (24.4 to 71.1)
Week 4947.4 (24.4 to 71.1)
Week 6142.1 (20.3 to 66.5)
Week 7336.8 (16.3 to 61.6)
Week 8531.6 (12.6 to 56.6)
Week 9731.6 (12.6 to 56.6)
Week 10931.6 (12.6 to 56.6)
Week 12136.8 (16.3 to 61.6)
Week 13331.6 (12.6 to 56.6)
Week 14526.3 (9.1 to 51.2)
Week 15710.5 (1.3 to 33.1)
SecondaryChange in the Amount of Corticosteroid Required Over Time

Change in the amount of corticosteroid required over time was reported.

Time frame:
Baseline, Weeks 24, 48, 96, and 144
Reported as:
Median · Milligrams per kilograms per day
Change in the Amount of Corticosteroid Required Over Time
Milligrams per kilograms per dayIbrutinib 420 mg
Baseline0.270 (0.08 to 1.77)
Week 240.250 (0.08 to 0.87)
Week 480.150 (0.06 to 0.64)
Week 960.140 (0.01 to 0.59)
Week 1440.140 (0.05 to 0.56)
SecondaryPercentage of Participants With Overall Improvement in Lee cGVHD Symptom Scale Score

Percentage of participants with overall improvement in Lee cGVHD symptom scale score was reported. Lee cGVHD symptom scale is a patient-reported symptom scale used to measure symptom burden and has 7 subscales (Skin, Eyes and Mouth, Breathing, Eating and Digestion, Muscles and Joints, Energy, and Mental and Emotional) with ratings as follows: 0-Not at all, 1-Slightly, 2-Moderately, 3-Quite a bit, 4-Extremely, with lower values representing a better outcome. A score was calculated for each subscale by taking the mean of all items completed if more than 50% were answered and normalizing to a 0 to 100 with a higher score indicating worse symptoms. An overall score was calculated as the average of these 7 subscales if at least 4 subscales had valid scores. A change of greater than or equal to (\>=) 7 points on the Lee cGVHD symptom scale overall score was considered significant and relates to improvement in quality of life (QoL).

Time frame:
Up to 3 year 6 months
Reported as:
Number · Percentage of participants
Percentage of Participants With Overall Improvement in Lee cGVHD Symptom Scale Score
Percentage of participantsIbrutinib 420 mg
Percentage of Participants With Overall Improvement in Lee cGVHD Symptom Scale Score52.6 (28.9 to 75.6)
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs are adverse events with onset during the treatment phase or that were a consequence of a preexisting condition that has worsened since baseline, and occurred during treatment or within 30 days following the last dose of study treatment, or any adverse event that was considered study treatment-related regardless of the start date of the event.

Time frame:
Up to 3 year 6 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsIbrutinib 420 mg
Number of Participants With Treatment-emergent Adverse Events (TEAEs)19
SecondaryArea Under the Plasma Concentration-time Curve From Time Zero to Time of Last Measurable Concentration (AUC [0-last]) of Ibrutinib

AUC(0-last) is defined as area under the plasma concentration-time curve from time zero to time of last measurable concentration of ibrutinib.

Time frame:
Day 1 of Weeks 1 and 2
Reported as:
Mean · hours*nanograms per milliliter (h*ng/mL)
Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Measurable Concentration (AUC [0-last]) of Ibrutinib
hours*nanograms per milliliter (h*ng/mL)Ibrutinib 420 mg
Week 1: Day 13683.7 ± 3146.9
Week 2: Day 14024.8 ± 4287.2
SecondaryArea Under the Plasma Concentration-time Curve From Time Zero to 24 Hours (AUC [0-24]) of Ibrutinib

AUC(0-24) is defined as area under the plasma concentration-time curve from time zero to 24 hours of ibrutinib.

Time frame:
0 to 24 hours (Day 1 of Weeks 1 and 2)
Reported as:
Mean · hour*ng/mL
Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours (AUC [0-24]) of Ibrutinib
hour*ng/mLIbrutinib 420 mg
Week 1: Day 12929.3 ± 1797.4
Week 2: Day 14035.6 ± 4277.2
SecondaryMaximum Observed Plasma Concentration (Cmax) of Ibrutinib

Cmax is defined as maximum observed plasma concentration of ibrutinib.

Time frame:
Day 1 of Weeks 1 and 2
Reported as:
Mean · Nanograms per milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) of Ibrutinib
Nanograms per milliliter (ng/mL)Ibrutinib 420 mg
Week 1: Day 1490.45 ± 366.07
Week 2: Day 1478.01 ± 508.08
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax) of Ibrutinib

Tmax is defined as time to reach the maximum observed plasma concentration of ibrutinib.

Time frame:
Day 1 of Weeks 1 and 2
Reported as:
Median · Hours
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Ibrutinib
HoursIbrutinib 420 mg
Week 1: Day 13.87 (1.78 to 5.75)
Week 2: Day 14.02 (1.75 to 5.43)
SecondaryElimination Half-Life (t1/2) of Ibrutinib

T1/2 is defined as elimination half-life of ibrutinib.

Time frame:
Day 1 of Weeks 1 and 2
Reported as:
Median · Hours
Elimination Half-Life (t1/2) of Ibrutinib
HoursIbrutinib 420 mg
Week 1: Day 14.9 (4.4 to 5.2)
Week 2: Day 14.4 (3.8 to 10.2)
SecondaryApparent Clearance (CL/F) of Ibrutinib

CL/F is defined as apparent clearance of ibrutinib.

Time frame:
Day 1 of Weeks 1 and 2
Reported as:
Mean · Milliliters per hour (mL/h)
Apparent Clearance (CL/F) of Ibrutinib
Milliliters per hour (mL/h)Ibrutinib 420 mg
Week 1: Day 1194211 ± 106164
Week 2: Day 1162457 ± 31966
SecondaryApparent Volume of Distribution (Vd/F) of Ibrutinib

Vd/F is defined as apparent volume of distribution of ibrutinib.

Time frame:
Day 1 of Weeks 1 and 2
Reported as:
Mean · Milliliters (mL)
Apparent Volume of Distribution (Vd/F) of Ibrutinib
Milliliters (mL)Ibrutinib 420 mg
Week 1: Day 11350160 ± 748511
SecondaryArea Under the Plasma Concentration-time Curve From Time Zero to Infinite Time (AUC[0-infinity]) of Ibrutinib

AUC(0-infinity) is defined as area under the plasma concentration-time curve from time zero to infinite time of ibrutinib.

Time frame:
Day 1 of Weeks 1 and 2
Reported as:
Mean · hour*ng/mL
Area Under the Plasma Concentration-time Curve From Time Zero to Infinite Time (AUC[0-infinity]) of Ibrutinib
hour*ng/mLIbrutinib 420 mg
Week 1: Day 12643.8 ± 1656.2
Week 2: Day 12659.2 ± 506.57
SecondaryArea Under the Plasma Concentration-time Curve From Time Zero to Time of Last Measurable Concentration (AUC [0-last]) of PCI-45227

AUC(0-last) is defined as area under the plasma concentration-time curve from time zero to time of last measurable concentration of PCI-45227.

Time frame:
Day 1 of Weeks 1 and 2
Reported as:
Mean · h*ng/mL
Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Measurable Concentration (AUC [0-last]) of PCI-45227
h*ng/mLIbrutinib 420 mg
Week 1: Day 11976.9 ± 968.83
Week 2: Day 12547.6 ± 999.00
SecondaryArea Under the Plasma Concentration-Time Curve From Time Zero to 24 Hours (AUC [0-24]) of PCI-45227

AUC(0-24) is defined as area under the plasma concentration-time curve from time zero to 24 hours of PCI-45227.

Time frame:
0 to 24 hours (Day 1 of Weeks 1 and 2)
Reported as:
Mean · hour*ng/mL
Area Under the Plasma Concentration-Time Curve From Time Zero to 24 Hours (AUC [0-24]) of PCI-45227
hour*ng/mLIbrutinib 420 mg
Week 1: Day 11803.0 ± 585.84
Week 2: Day 12547.6 ± 999.00
SecondaryMaximum Observed Plasma Concentration (Cmax) of PCI-45227

Cmax is defined as maximum observed plasma concentration of PCI-45227.

Time frame:
Day 1 of Weeks 1 and 2
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of PCI-45227
ng/mLIbrutinib 420 mg
Week 1: Day 1185.37 ± 91.874
Week 2: Day 1203.16 ± 82.292
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax) of PCI-45227

Tmax is defined as time to reach the maximum observed plasma concentration of PCI-45227.

Time frame:
Day 1 of Weeks 1 and 2
Reported as:
Median · Hours
Time to Reach Maximum Observed Plasma Concentration (Tmax) of PCI-45227
HoursIbrutinib 420 mg
Week 1: Day 14.00 (1.88 to 6.18)
Week 2: Day 14.02 (0.00 to 5.28)
SecondaryElimination Half-Life (t1/2) of PCI-45227

T1/2 is defined as elimination half-life of PCI-45227.

Time frame:
Day 1 of Weeks 1 and 2
Reported as:
Median · Hours
Elimination Half-Life (t1/2) of PCI-45227
HoursIbrutinib 420 mg
Week 1: Day 15.9 (5.2 to 6.5)
Week 2: Day 15.4 (5.4 to 5.4)
SecondaryApparent Clearance (CL/F) of PCI-45227

CL/F is defined as apparent clearance of PCI-45227.

Time frame:
Day 1 of Weeks 1 and 2
Reported as:
Mean · mL/h
Apparent Clearance (CL/F) of PCI-45227
mL/hIbrutinib 420 mg
Week 1: Day 1251681 ± 68392
Week 2: Day 1111922 ± NA
SecondaryApparent Volume of Distribution (Vd/F) of PCI-45227

Vd/F is defined as apparent volume of distribution of PCI-45227.

Time frame:
Day 1 of Weeks 1 and 2
Reported as:
Mean · mL
Apparent Volume of Distribution (Vd/F) of PCI-45227
mLIbrutinib 420 mg
Week 1: Day 12148283 ± 653626
SecondaryArea Under the Plasma Concentration-time Curve From Time Zero to Infinite Time (AUC[0-infinity]) of PCI-45227

AUC(0-infinity) is defined as area under the plasma concentration-time curve from time zero to infinite time of PCI-45227.

Time frame:
Day 1 of Weeks 1 and 2
Reported as:
Mean · hour*ng/mL
Area Under the Plasma Concentration-time Curve From Time Zero to Infinite Time (AUC[0-infinity]) of PCI-45227
hour*ng/mLIbrutinib 420 mg
Week 1: Day 11766.1 ± 478.74
Week 2: Day 13752.6 ± NA

Adverse events

Collected over Up to 3 year 6 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ibrutinib 420 mg7/19 (36.8%)12/19 (63.2%)19/19 (100%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventIbrutinib 420 mg
PneumoniaInfections and infestations7/19
CellulitisInfections and infestations3/19
Renal ImpairmentRenal and urinary disorders2/19
Immune ThrombocytopeniaBlood and lymphatic system disorders1/19
Atrial FlutterCardiac disorders1/19
CataractEye disorders1/19
Gastrointestinal HaemorrhageGastrointestinal disorders1/19
Multiple Organ Dysfunction SyndromeGeneral disorders1/19
Liver DisorderHepatobiliary disorders1/19
Anaphylactic ReactionImmune system disorders1/19
Most frequent other events
Showing 10 of 150
Most frequent other events
EventIbrutinib 420 mg
StomatitisGastrointestinal disorders9/19
CellulitisInfections and infestations6/19
Upper Respiratory Tract InfectionInfections and infestations6/19
Platelet Count DecreasedInvestigations6/19
NauseaGastrointestinal disorders5/19
PneumoniaInfections and infestations5/19
CataractEye disorders4/19
ConstipationGastrointestinal disorders4/19
Oedema PeripheralGeneral disorders4/19
HeadacheNervous system disorders4/19

Baseline characteristics

Age, Continuous
Age, Continuous(years)Ibrutinib 420 mg
Mean40.5 ± 16.24
Age, Customized
Age, Customized(Participants)Ibrutinib 420 mg
Less Than or Equal to 17 years (adolescent)1
From 18 to 64 years18
Sex: Female, Male
Sex: Female, Male(Participants)Ibrutinib 420 mg
Female7
Male12
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ibrutinib 420 mg
Hispanic or Latino0
Not Hispanic or Latino19
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ibrutinib 420 mg
American Indian or Alaska Native0
Asian19
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Ibrutinib 420 mg
JAPAN19
08

Study locations

15 sites
  • Anjo Kosei Hospital
    Anjo-shi, 446-8602, Japan
  • Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
    Bunkyo ku, 113 8677, Japan
  • Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital
    Hiroshima, 730-8619, Japan
  • Tokai University Hospital
    Isehara, 259-1193, Japan
  • Osaka Women's and Children's Hospital
    Izumi, 594-1101, Japan
  • Kobe City Medical Center General Hospital
    Kobe City, 650 0047, Japan
  • National Hospital Organization Kumamoto Medical Center
    Kumamoto-shi, 860-0008, Japan
  • Kurashiki Central Hospital
    Kurashiki, 710-8602, Japan
  • Gunmaken Saiseikai Maebashi Hospital
    Maebashi, 371-0821, Japan
  • Japanese Red Cross Nagoya Daiichi Hospital
    Nagoya, 453-8511, Japan
  • The Hospital of Hyogo College of Medicine
    Nishinomiya, 663-8501, Japan
  • Okayama University Hospital
    Okayama, 700 8558, Japan
  • Osaka City University Hospital
    Osaka, 545 8586, Japan
  • Hokkaido University Hospital
    Sapporo-shi, 060-8648, Japan
  • National Center for Child Health and Development
    Setagaya Ku, 157 8535, Japan
09

References and documents

Publications

  • Doki N, Toyosaki M, Shiratori S, Osumi T, Okada M, Kawakita T, Sawa M, Ishikawa T, Ueda Y, Yoshinari N, Nakahara S. An Open-Label, Single-Arm, Multicenter Study of Ibrutinib in Japanese Patients With Steroid-dependent/Refractory Chronic Graft-Versus-Host Disease. Transplant Cell Ther. 2021 Oct;27(10):867.e1-867.e9. doi: 10.1016/j.jtct.2021.05.019. Epub 2021 Jun 6. PubMed 34102349 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in Nov 2021, 42 months.

Results were first posted in Feb 2023, 1 year 2 months after primary completion.

Of 31 phase 3 interventional studies under Graft vs Host Disease, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 48. This study's 42 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2018
First posted
Mar 22, 2018
StartActual
May 1, 2018
Primary completionActual
Nov 29, 2021
CompletionActual
Nov 29, 2021
Results first posted
Feb 3, 2023
Last update
Feb 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03474679
Responsible party
Sponsor
First posted
Mar 22, 2018
Start date
May 1, 2018
Primary completion
Nov 29, 2021
Completion
Nov 29, 2021
Results posted
Feb 3, 2023
Last update
Feb 4, 2025

Study contacts

Janssen Pharmaceutical K.K., Japan Clinical Trial
study director · Janssen Pharmaceutical K.K.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibrutinib

Start the discussion